Biotech Values | Forum profile

Are you thinking about how you might answer it, or is your question meant to be taken as philosophical and rhetorical? I may or may not spend the time to answer that and the other questions I would need to have answered. Not my highest priority task. OTOH if the price drops precipitiously the priority would increase.

Aftershocks Felt From Iceland http://online.wsj.com/article/SB122345583528614761 .html ›'Like Lehman,' the Small Nation's Turmoil Has Far-Reaching Economic Effects By JEANNE WHALEN in London and CHARLES FORELLE in Reykjavík OCTOBER 9, 2008 Ripples from the financial collapse in Iceland struck savers and governments elsewhere in Europe on Wednesday, in what economists ...

>DNDN – It all hinges on whether you believe that it is coincidence or truth that HR improved very substantially over time with 9901 and 9902a… The question is what was the chance of that happening by good fortune. Until I have answered that question, I personally will not invest even if I am hopeful for moral reasons.< Are you thinking about how you might answer it, or is your ...

Under most sets of reasonable assumptions, hitting the required HR threshold at the final analysis is no cakewalk. It all hinges on whether you believe that it is coincidence or truth that HR improved very substantially over time with 9901 and 9902a. In both it improved more than 50% after placebo median. The question is what was the chance of that happening by good fortune. Until...

DNDN – Let’s run some pseudo HR numbers: >[PGS to iwfal]: If they need a 22% reduction in the risk of death at final analysis, and you believe the curves get stronger from here on out, it seems to be a good bet, no?< Let’s define pseudo HR as a first-order linear approximation for the HR during a given portion of a trial (in this case 9902b). Without loss of generality, we ...

Excellent read: "How Doctors Think" by Jerome Groopman, MD Great book, IMHO, by an MD that reviews, chapter by chapter, the various ways that a medical doctor's preconceived notions can keep them from listening to patients carefully. It describes how easy it is for both patient and doctor to bow to the pressures of easy diagnoses, time, and the desire to see what the patient or ...

At least one healthcare-related deal has been undone by the turbulence in the financial markets: Walgreen pulled its offer to acquire Longs Drug Stores, allowing archrival CVS to win the bidding war by default. http://biz.yahoo.com/rb/081008/business_us_longs_w algreen.html

Meanwhile, it’s becoming somewhat easier for drug companies to disseminate DTC information in Europe: http://online.wsj.com/article/SB122340544043612127 .html › Europe Mulls Easing Drug Rules OCTOBER 8, 2008 By JEANNE WHALEN Europe is poised to relax restrictions preventing drug companies from reaching out to consumers. Unlike in the U.S., drug companies ...

upcoming events this month: Event Date Brand Name Event Originator Licensee(s) Therapeutic Categories Pharma Class 14-Oct-08 Femara (Litigation) Motion Hearing (Mylan case) Novartis AG Cancer Aromatase Inhibitors 14-Oct-08 Cinryze (Product) PDUFA expected Lev Pharmaceuticals, Inc. Cardiovascular Enzyme Inhibitors 15-Oct-08 Acapodene (Product) FDA guidance expected GTx Inc....

thanks Dew!

pharmawire article - 02-Oct-08 21:07 Genentech: Roche financing is 'not a problem', insider says Story Roche does "not have a problem" with financing the USD 43.7bn bid for Genentech, according to an insider at Roche. Despite reports that Roche is facing difficulties securing the funds, the insider confirmed it has not been a problem. "To me, it's a done deal. It's just a matter of time...

Aftershocks Felt From Iceland http://online.wsj.com/article/SB122345583528614761 .html ›'Like Lehman,' the Small Nation's Turmoil Has Far-Reaching Economic Effects By JEANNE WHALEN in London and CHARLES FORELLE in Reykjavík OCTOBER 9, 2008 Ripples from the financial collapse in Iceland struck savers and governments elsewhere in Europe on Wednesday, in what economists ...

Excellent read: "How Doctors Think" by Jerome Groopman, MD Great book, IMHO, by an MD that reviews, chapter by chapter, the various ways that a medical doctor's preconceived notions can keep them from listening to patients carefully. It describes how easy it is for both patient and doctor to bow to the pressures of easy diagnoses, time, and the desire to see what the patient or ...

>DNDN – It all hinges on whether you believe that it is coincidence or truth that HR improved very substantially over time with 9901 and 9902a… The question is what was the chance of that happening by good fortune. Until I have answered that question, I personally will not invest even if I am hopeful for moral reasons.< Are you thinking about how you might answer it, or is your ...

DNDN – Let’s run some pseudo HR numbers: >[PGS to iwfal]: If they need a 22% reduction in the risk of death at final analysis, and you believe the curves get stronger from here on out, it seems to be a good bet, no?< Let’s define pseudo HR as a first-order linear approximation for the HR during a given portion of a trial (in this case 9902b). Without loss of generality, we ...

At least one healthcare-related deal has been undone by the turbulence in the financial markets: Walgreen pulled its offer to acquire Longs Drug Stores, allowing archrival CVS to win the bidding war by default. http://biz.yahoo.com/rb/081008/business_us_longs_w algreen.html

upcoming events this month: Event Date Brand Name Event Originator Licensee(s) Therapeutic Categories Pharma Class 14-Oct-08 Femara (Litigation) Motion Hearing (Mylan case) Novartis AG Cancer Aromatase Inhibitors 14-Oct-08 Cinryze (Product) PDUFA expected Lev Pharmaceuticals, Inc. Cardiovascular Enzyme Inhibitors 15-Oct-08 Acapodene (Product) FDA guidance expected GTx Inc....

Meanwhile, it’s becoming somewhat easier for drug companies to disseminate DTC information in Europe: http://online.wsj.com/article/SB122340544043612127 .html › Europe Mulls Easing Drug Rules OCTOBER 8, 2008 By JEANNE WHALEN Europe is poised to relax restrictions preventing drug companies from reaching out to consumers. Unlike in the U.S., drug companies ...

thanks Dew!

does anyone know anything about this? Swiss news agency, Swisster, reporting that Roche secured the financing for the purchase of DNA @ $89 and that their still could be a higher offer at $96.75. true false??